FY2021 EPS Estimates for Exelixis, Inc. Raised by Truist Securities (NASDAQ:EXEL)

Exelixis, Inc. (NASDAQ:EXEL) – Stock analysts at Truist Securities upped their FY2021 earnings per share (EPS) estimates for shares of Exelixis in a research report issued to clients and investors on Tuesday, January 11th. Truist Securities analyst A. Goonewardene now forecasts that the biotechnology company will post earnings per share of $0.46 for the year, up from their prior estimate of $0.42. Truist Securities has a “Buy” rating and a $36.00 price objective on the stock. Truist Securities also issued estimates for Exelixis’ Q4 2021 earnings at $0.04 EPS, FY2022 earnings at $0.88 EPS, FY2023 earnings at $1.22 EPS, FY2024 earnings at $1.56 EPS, FY2025 earnings at $1.99 EPS and FY2026 earnings at $2.36 EPS.

EXEL has been the topic of several other research reports. Piper Sandler started coverage on Exelixis in a report on Friday, November 19th. They set an “overweight” rating and a $34.00 price objective on the stock. Jefferies Financial Group started coverage on Exelixis in a report on Wednesday, October 6th. They set a “buy” rating and a $28.00 price objective on the stock. TheStreet downgraded Exelixis from a “b-” rating to a “c” rating in a report on Thursday, November 4th. HC Wainwright cut their price objective on Exelixis from $65.00 to $52.00 and set a “buy” rating on the stock in a report on Wednesday, November 3rd. Finally, Royal Bank of Canada cut their target price on Exelixis from $32.00 to $31.00 and set an “outperform” rating on the stock in a report on Wednesday, November 3rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $32.18.

NASDAQ EXEL opened at $18.12 on Thursday. Exelixis has a twelve month low of $15.50 and a twelve month high of $25.77. The company has a market cap of $5.73 billion, a price-to-earnings ratio of 35.53, a price-to-earnings-growth ratio of 0.57 and a beta of 0.89. The business’s fifty day moving average is $17.86 and its 200 day moving average is $18.80.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, November 2nd. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.19 by ($0.07). Exelixis had a net margin of 13.10% and a return on equity of 8.27%. The business had revenue of $328.42 million during the quarter, compared to the consensus estimate of $366.34 million. During the same quarter in the previous year, the business posted ($0.10) EPS.

In other news, EVP Peter Lamb sold 47,500 shares of the business’s stock in a transaction dated Monday, November 15th. The stock was sold at an average price of $18.09, for a total value of $859,275.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Carl B. Feldbaum sold 20,000 shares of the business’s stock in a transaction dated Friday, November 19th. The shares were sold at an average price of $17.62, for a total value of $352,400.00. The disclosure for this sale can be found here. Insiders sold a total of 137,353 shares of company stock worth $2,450,124 over the last three months. 3.30% of the stock is owned by company insiders.

A number of institutional investors have recently modified their holdings of the stock. Scout Investments Inc. increased its position in Exelixis by 15.4% in the 4th quarter. Scout Investments Inc. now owns 1,477,597 shares of the biotechnology company’s stock valued at $27,010,000 after buying an additional 196,673 shares in the last quarter. Louisiana State Employees Retirement System increased its position in Exelixis by 1.2% in the 4th quarter. Louisiana State Employees Retirement System now owns 81,400 shares of the biotechnology company’s stock valued at $1,488,000 after buying an additional 1,000 shares in the last quarter. IFP Advisors Inc increased its position in Exelixis by 22.6% in the 4th quarter. IFP Advisors Inc now owns 9,075 shares of the biotechnology company’s stock valued at $166,000 after buying an additional 1,674 shares in the last quarter. DNB Asset Management AS increased its position in Exelixis by 4.2% in the 4th quarter. DNB Asset Management AS now owns 19,831 shares of the biotechnology company’s stock valued at $363,000 after buying an additional 808 shares in the last quarter. Finally, Patriot Financial Group Insurance Agency LLC increased its position in Exelixis by 6.9% in the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 38,765 shares of the biotechnology company’s stock valued at $709,000 after buying an additional 2,500 shares in the last quarter. 82.96% of the stock is owned by institutional investors and hedge funds.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B.

See Also: Strangles

Earnings History and Estimates for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.